FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018093390> ?p ?o ?g. }

• W2018093390 endingPage "2273" @default.
• W2018093390 startingPage "2267" @default.
• W2018093390 abstract "Although cytotoxic chemotherapy is widely used in advanced breast cancer, there are no powerful predictors for the therapy response. Because topoisomerase IIalpha (Topo IIalpha) is the molecular target for the anthracycline class of anti-cancer drugs, we compared the immunocytochemical assay of Topo IIalpha with other biomarkers in the prediction of clinical response to Topo II inhibitor chemotherapy. Fifty-five patients with advanced breast cancer were treated with a single cytotoxic drug, Topo II-inhibitor, epirubicin (30 mg m(-2) weekly up to 1000 mg m(-2)), as first line cytotoxic chemotherapy. Objective response to treatment was analysed according to UICC criteria. The predictive value of Topo IIalpha expression, c-erbB2 oncoprotein, p53 tumour-suppressor protein, oestrogen (ER) and progesterone receptor (PR), S-phase fraction and DNA ploidy were analysed from representative formalin-fixed paraffin-embedded primary tumour samples. The proportion of Topo IIalpha-positive cells (Topo IIalpha index) failed to predict response to epirubicin therapy. Mean Topo IIalpha scores in 29 responding patients were similar when compared with those with no change in disease progression (n = 13) and those with progressive disease (n = 13) (14.9% +/- 11.4% vs 15.5% +/- 7.6% vs 17.3% +/- 13.2%, not significant). Among the other biomarkers tested, overexpression of c-erbB2 oncoprotein and hormone receptor negativity were significantly associated with poor response. Response rate in patients with c-erbB2-overexpressing tumours was 32% compared with 65% in patients with no c-erbB2 overexpression (P = 0.0058). Accordingly, the response rate for ER-positive patients was 67% compared with 26% in ER-negative patients (P = 0.0021). Although both negative ER status and c-erbB2 overexpression are associated with high Topo IIalpha expression in breast cancer, step-wise logistic regression analysis showed that ER and c-erbB2 were associated with therapy response independent of Topo IIalpha expression. Histological grade, p53, DNA-ploidy, tumour proliferation rate (S-phase fraction), stage of the disease at diagnosis, age of the patient, previous anti-oestrogen therapy or site of metastasis did not predict the response to epirubicin therapy. In conclusion, despite extensive in vitro evidence, expression of Topo IIalpha is unlikely to predict the response to Topo II inhibitor chemotherapy in advanced breast cancer. Among the prognostic biomarkers, overexpression of c-erbB2 oncogene and negative ER may have predictive value in epirubicin therapy in patients with advanced breast cancer." @default.
• W2018093390 created "2016-06-24" @default.
• W2018093390 creator A5025365158 @default.
• W2018093390 creator A5067443922 @default.
• W2018093390 creator A5068108014 @default.
• W2018093390 creator A5073491611 @default.
• W2018093390 date "1998-06-01" @default.
• W2018093390 modified "2023-10-10" @default.
• W2018093390 title "Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer" @default.
• W2018093390 cites W1498953001 @default.
• W2018093390 cites W1525712969 @default.
• W2018093390 cites W1545715398 @default.
• W2018093390 cites W1552550535 @default.
• W2018093390 cites W168811426 @default.
• W2018093390 cites W180022983 @default.
• W2018093390 cites W1821522531 @default.
• W2018093390 cites W1853410251 @default.
• W2018093390 cites W1964441327 @default.
• W2018093390 cites W1965421358 @default.
• W2018093390 cites W1970039444 @default.
• W2018093390 cites W1972227366 @default.
• W2018093390 cites W1983354903 @default.
• W2018093390 cites W1984274637 @default.
• W2018093390 cites W1987912912 @default.
• W2018093390 cites W1992091679 @default.
• W2018093390 cites W1992211004 @default.
• W2018093390 cites W1996982054 @default.
• W2018093390 cites W2002109198 @default.
• W2018093390 cites W2008143315 @default.
• W2018093390 cites W2011932334 @default.
• W2018093390 cites W2020787388 @default.
• W2018093390 cites W2023758607 @default.
• W2018093390 cites W2024497944 @default.
• W2018093390 cites W2027151723 @default.
• W2018093390 cites W2028823791 @default.
• W2018093390 cites W2030295874 @default.
• W2018093390 cites W2035922694 @default.
• W2018093390 cites W2036329178 @default.
• W2018093390 cites W2058681718 @default.
• W2018093390 cites W2060591138 @default.
• W2018093390 cites W2061563172 @default.
• W2018093390 cites W2074017881 @default.
• W2018093390 cites W2080687440 @default.
• W2018093390 cites W2089799642 @default.
• W2018093390 cites W2089923996 @default.
• W2018093390 cites W2098567881 @default.
• W2018093390 cites W2103489107 @default.
• W2018093390 cites W2132979902 @default.
• W2018093390 cites W2137501619 @default.
• W2018093390 cites W2140600345 @default.
• W2018093390 cites W2163971502 @default.
• W2018093390 cites W2171210450 @default.
• W2018093390 cites W2247784986 @default.
• W2018093390 cites W2323425273 @default.
• W2018093390 cites W2328452031 @default.
• W2018093390 cites W2413499351 @default.
• W2018093390 cites W2417845837 @default.
• W2018093390 cites W267005183 @default.
• W2018093390 cites W50210946 @default.
• W2018093390 cites W78711663 @default.
• W2018093390 doi "https://doi.org/10.1038/bjc.1998.377" @default.
• W2018093390 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2150425" @default.
• W2018093390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9649144" @default.
• W2018093390 hasPublicationYear "1998" @default.
• W2018093390 type Work @default.
• W2018093390 sameAs 2018093390 @default.
• W2018093390 citedByCount "137" @default.
• W2018093390 countsByYear W20180933902012 @default.
• W2018093390 countsByYear W20180933902013 @default.
• W2018093390 countsByYear W20180933902014 @default.
• W2018093390 countsByYear W20180933902017 @default.
• W2018093390 countsByYear W20180933902020 @default.
• W2018093390 countsByYear W20180933902021 @default.
• W2018093390 countsByYear W20180933902022 @default.
• W2018093390 crossrefType "journal-article" @default.
• W2018093390 hasAuthorship W2018093390A5025365158 @default.
• W2018093390 hasAuthorship W2018093390A5067443922 @default.
• W2018093390 hasAuthorship W2018093390A5068108014 @default.
• W2018093390 hasAuthorship W2018093390A5073491611 @default.
• W2018093390 hasBestOaLocation W20180933901 @default.
• W2018093390 hasConcept C121608353 @default.
• W2018093390 hasConcept C126322002 @default.
• W2018093390 hasConcept C143998085 @default.
• W2018093390 hasConcept C147897179 @default.
• W2018093390 hasConcept C181199279 @default.
• W2018093390 hasConcept C2776694085 @default.
• W2018093390 hasConcept C2776802502 @default.
• W2018093390 hasConcept C2777292972 @default.
• W2018093390 hasConcept C2780835546 @default.
• W2018093390 hasConcept C2781303535 @default.
• W2018093390 hasConcept C502942594 @default.
• W2018093390 hasConcept C530470458 @default.
• W2018093390 hasConcept C55493867 @default.
• W2018093390 hasConcept C71924100 @default.
• W2018093390 hasConcept C86803240 @default.
• W2018093390 hasConceptScore W2018093390C121608353 @default.
• W2018093390 hasConceptScore W2018093390C126322002 @default.
• W2018093390 hasConceptScore W2018093390C143998085 @default.

• next